This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Phase 3 data expected in the second half of 2024
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
PhytoSquene now available for clinical and commercial use
Subscribe To Our Newsletter & Stay Updated
